New crystal form of rosemeltirol and preparation method thereof

Through the new preparation method, the solvent residue problem of rismetiro crystal form in industrial production was solved, and a new crystal form APTI-I with high stability and high solubility was obtained. It is suitable for drug preparation production and feasible for industrial applications. sex.

CN119019375AInactive Publication Date: 2024-11-26AURISCO PHARM(TIANJIN) INC
View PDF 0 Cites 7 Cited by

Patent Information

Application Number
CN202411110874.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing rismetiro crystal form has solvent residue problems in large-scale industrial production, which is difficult to meet the medicinal requirements, and the high-temperature solvent desolvation method is not suitable for industrial applications.

Method used

Using a new preparation method, the new crystal APTI of rismetiol was obtained by mixing it with hydrophilic organic solvent and adding alkali to form a salt, and mixing it with an ether organic solvent and adding acid. -I, with high stability, low hygroscopicity and high solubility.

Benefits of technology

It has achieved high purity, high yield, and good solubility in water solvents of different pHs. It is suitable for industrial production as a pharmaceutical preparation, and the production method is simple and the quality is stable.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention provides a novel crystal form and a novel crystal form APTI-I. The novel crystal form and the novel crystal form APTI-I are radiated by Cu-K alpha, and an X-ray powder diffraction pattern represented by a 2 theta angle has characteristic peaks at 5.0 degrees + / -0.2 degrees, 6.3 degrees + / -0.2 degrees, 7.8 degrees + / -0.2 degrees, 12.2 degrees + / -0.2 degrees and 20.0 degrees + / -0.2 degrees. The crystal form is easy to prepare, high in purity, good in stability and good in solubility in a water solvent, and is suitable for industrial large-scale production and preparation of pharmaceutical preparations.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention specifically relates to a new crystal form of Resmetirom, APTI-I, and a preparation method thereof, and belongs to the field of pharmaceutical crystal chemistry. Background Art

[0002] Metabolic dysfunction-associated steatohepatitis (MASH) is a complex liver disease caused by obesity and diabetes, which may lead to liver fibrosis, liver failure and even liver cancer. According to the latest epidemiological studies, approximately 5% of adults worldwide are affected by MASH. As the first drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of MASH, Resmetirom has shown significant effects in reducing the formation of liver scar tissue and improving other hallmark symptoms of the disease. By enhancing the liver's response to thyroid hormones, Resmetirom stimulates the liver to metabolize fatty acids, thereby reducing inflammation and fat accumulation, bringing hope to MASH patients.

[0003] Resmetiro is currently mainly administered in the form of resmetiro free base, and its chemical structure is shown in formula (I).

[0004]

[0005] It is well known that different spatial arrangements of drug molecules will form different crystal forms, and different crystal forms will exhibit different physical and chemical properties such as stability, solubility, and hygroscopicity.

[0006] The current research on resmetiro crystal form is as follows:

[0007] Prior art WO2014043706 discloses a crystal form of resmetiro Form I, which is the crystal form used in the currently commercially available resmetiro pharmaceutical preparations. The prior art discloses a method for preparing the crystal form Form I, including three methods, the first method is: first preparing resmetiro as a MIBK solvate, then refluxing and slurrying the MIBK solvate in ethanol, and finally cooling to room temperature to prepare the crystal form Form I; the second method is: first preparing resmetiro as an N,N-dimethylacetamide (DMAC) solvate, then refluxing the N,N-dimethylacetamide solvate in ethanol, and finally cooling to room temperature to prepare the crystal form Form I, and the third method is: heating a mixture of the N,N-dimethylacetamide solvate of resmetiro and the dihydrate of resmetiro in MIBK to 80°C, cooling to room temperature, and preparing the crystal form Form I. The inventors of the present application repeated the first method and found that there was a risk of forming resmetirole ethanol solvate during the process of ethanol slurrying and cooling the MIBK solvate to room temperature to prepare the crystalline Form I. According to the ICH requirements, the ethanol content is not higher than 5000ppm. Once the ethanol solvate is formed, the residual solvent will be much higher than this standard and cannot be used as a raw material.

[0008] Prior art WO2020010068 discloses a variety of anhydrous crystalline forms and solvates of resmetiro, but the solvent residues of all solvates cannot meet the requirements for pharmaceutical use, and a variety of anhydrous crystalline forms are obtained by desolvation of solvates. The inventors of the present application have studied the ethyl acetate solvate and found that the temperature required for desolvation of the solvate is relatively high and cannot be industrialized for large-scale production. In addition, high-temperature desolvation is usually difficult to solve the problem of solvent residues.

[0009] The prior art WO2022086894 and CN114907327A also disclose various solvates of resmetirole, but these solvates also cannot meet the pharmaceutical requirements due to the problem of residual organic solvents.

[0010] Therefore, it is necessary to develop a better crystal form of resmetiro to facilitate industrial large-scale production and improve its existing physical and chemical properties to make it more suitable for the preparation of pharmaceutical preparations. Summary of the invention

[0011] In view of the defects of the resmetiro crystal form in the prior art, the present invention provides a new crystal form of resmetiro (crystal form APTI-I), which is suitable for large-scale industrial production, has high yield, high purity, stable physical and chemical properties under high temperature conditions and good solubility in aqueous solvents of different pH values, and is suitable as a crystal form for preparing pharmaceutical preparations.

[0012] The resmetirole crystal form APTI-I provided by the present invention uses Cu-Kα radiation, and its X-ray powder diffraction pattern represented by 2θ angles has characteristic peaks at 5.0°±0.2°, 6.3°±0.2°, 7.8°±0.2°, 12.2°±0.2°, and 20.0°±0.2°.

[0013] In another preferred embodiment, the resmetirome crystal form APTI-I, using Cu-Kα radiation, has an X-ray powder diffraction pattern expressed in 2θ angles, and has characteristic peaks at any one or more of 8.5°±0.2°, 10.1°±0.2°, 14.4°±0.2°, 15.1°±0.2°, 16.5°±0.2°, 16.9°±0.2°, 17.9°±0.2°, 20.4°±0.2°, 20.9°±0.2°, 22.0°±0.2°, 23.0°±0.2°, 23.8°±0.2°, 25.3°±0.2°, and 26.4°±0.2°.

[0014] In another preferred embodiment, the X-ray powder diffraction pattern of the resmetirol crystal form APTI-I is substantially as follows Figure 1 shown.

[0015] In another preferred embodiment, the differential scanning calorimetry diagram of the resmetirome crystal form APTI-I has an exothermic peak at 237±5°C and an endothermic peak at 330±5°C.

[0016] In another preferred embodiment, the differential scanning calorimetry analysis diagram of the resmetiro crystal form APTI-I is substantially as follows Figure 2 shown.

[0017] In another preferred embodiment, the thermogravimetric analysis of the resmetirome crystal form APTI-I shows a weight loss of about 2.7% at 40°C to 160°C.

[0018] In another preferred embodiment, the thermogravimetric analysis diagram of the resmetiro crystal form APTI-I is substantially as follows Figure 3 shown.

[0019] The present invention also provides a method for preparing the above-mentioned resmetirome crystal form APTI-I, and the preparation method comprises the following steps:

[0020] (1) mixing resmetiro with a first organic solvent, adding a base to the mixture to form a salt of resmetiro and dissolve it, filtering, and concentrating the filtrate to dryness to obtain an amorphous form of resmetiro salt;

[0021] (2) mixing the amorphous resmetiro salt with a second organic solvent, adding an acid to the mixture to free the resmetiro salt, filtering the mixture, and drying the filter cake to obtain resmetiro crystal form APTI-I.

[0022] In another preferred embodiment, the first organic solvent is a hydrophilic organic solvent. In another preferred embodiment, the second organic solvent is an ether organic solvent. In another preferred embodiment, the base is an aqueous solution of an inorganic base. In another preferred embodiment, the acid is an aqueous solution of an inorganic acid.

[0023] In another preferred embodiment, the hydrophilic organic solvent is selected from methanol, ethanol, n-propanol, isopropanol, acetone, 2-butanone, acetonitrile, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, N,N-dimethylacetamide or a combination thereof, more preferably, tetrahydrofuran.

[0024] In another preferred embodiment, the ether organic solvent is selected from methyl tert-butyl ether, isopropyl ether, cyclopentyl methyl ether or a combination thereof, more preferably, methyl tert-butyl ether.

[0025] In another preferred embodiment, the inorganic base is selected from sodium hydroxide, potassium hydroxide, ammonia water or a combination thereof, more preferably, sodium hydroxide.

[0026] In another preferred embodiment, the inorganic acid is selected from hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid or a combination thereof, more preferably, hydrochloric acid.

[0027] In another preferred embodiment, the weight-to-volume ratio of resmetiro to the hydrophilic organic solvent is 1 g / 3 mL to 15 mL, more preferably, 1 g / 4 mL to 6 mL.

[0028] In another preferred embodiment, the weight-to-volume ratio of resmetiro salt to the ether organic solvent is 1 g / 4 mL to 20 mL, more preferably, 1 g / 8 mL to 12 mL.

[0029] In another preferred embodiment, the molar ratio of resmetirole to the hydroxide provided by the inorganic base is 1:1.0-2.0, more preferably 1:1.0-1.2, and most preferably 1:1.1.

[0030] In another preferred embodiment, the molar ratio of hydrogen ions provided by the inorganic acid to hydroxide ions provided by the base is 1:0.8-1.2, more preferably 1:1.

[0031] In another preferred embodiment, the molar concentration of the aqueous solution of the inorganic base is 1 mol / L to 3 mol / L.

[0032] In another preferred embodiment, the molar concentration of the aqueous solution of the inorganic acid is 1 mol / L to 3 mol / L.

[0033] In another preferred embodiment, in step (2), the drying temperature is 40°C to 85°C, and the drying time is 10h to 24h. More preferably, the drying temperature is 50°C to 70°C, and the drying time is 12h to 20h.

[0034] In another preferred embodiment, in step (1), resmetirol is mixed with the first organic solvent and stirred at 35°C to 65°C for 0.5h to 2.0h, then a base is added, and the filtration temperature is 0 to 40°C.

[0035] In another preferred embodiment, in step (2), the amorphous form of resmetiro salt is mixed with the second organic solvent and stirred at 35°C to 65°C for 0.5h to 2.0h, and then the acid is added, and the filtration temperature is 0 to 40°C.

[0036] In another aspect, the present invention provides a pharmaceutical composition comprising the above-mentioned resmetirome crystal form APTI-I. BRIEF DESCRIPTION OF THE DRAWINGS

[0037] Figure 1 This is a typical XRPD pattern of resmetirole crystalline form APTI-I;

[0038] Figure 2 This is a typical DSC spectrum of resmetirol crystalline form APTI-I;

[0039] Figure 3 This is a typical TGA spectrum of resmetirome crystal form APTI-I;

[0040] Figure 4a This is a typical PLM spectrum of resmetirol crystalline form APTI-I;

[0041] Figure 4b This is the H-NMR spectrum of resmetirol crystalline form APTI-I;

[0042] Figure 5 It is an overlay of the XRPD spectrum of the product obtained by repeating the process of obtaining the crystal form Form I in the prior art WO2014043706;

[0043] Figure 6 It is a DSC graph of resmetiro ethyl acetate solvate obtained by repeating the prior art WO2020010068;

[0044] Figure 7 It is an overlay of the XRPD pattern of the ethyl acetate solvate of resmetirole obtained by repeating the prior art WO2020010068 and the XRPD pattern of the crystalline form Form F obtained by desolvation thereof;

[0045] Figure 8 This is an XRPD overlay of the starting material (crystalline APTI-I) and the product obtained after manual dry grinding in an agate grinder for 30 minutes during the grinding stability experiment of crystalline APTI-I;

[0046] Fig. 9It is an overlay of the XRPD patterns of the starting material (crystalline APTI-I) and the product obtained after being placed in an oven at 80°C for 24 hours during the high temperature stability test of crystalline APTI-I;

[0047] Fig.10 It is an overlay of the XRPD patterns of the starting material (crystalline APTI-I) and the product obtained after being placed in a constant temperature and humidity chamber at 25°C / 80%RH for 24 hours during the hygroscopicity experiment of crystalline APTI-I;

[0048] Fig.11 It is an overlay of XRPD patterns of the products obtained during the constant temperature and humidity stability experiment of resmetiro crystal form APTI-I, namely, the starting material (crystal form APTI-I), the product packaged in PE bags and aluminum foil bags (that is, the product has two layers of packaging, first in PE bags and then in aluminum foil bags) and placed at 25°C / 60% RH for 1 week, the product packaged in PE bags and aluminum foil bags and placed at 40°C / 75% RH for 1 week, the product packaged in PE bags and aluminum foil bags and placed at 25°C / 60% RH for 2 weeks, and the product packaged in PE bags and aluminum foil bags and placed at 40°C / 75% RH for 2 weeks.

[0049] Fig.12 This is the XRPD spectrum of the amorphous form of resmetiro sodium salt obtained in Example 1.

[0050] Fig.13 This is the H NMR spectrum of resmetiro sodium salt obtained in Example 1. DETAILED DESCRIPTION

[0051] The inventors of the present application have obtained a new crystal form of resmetirox, crystal form APTI-I, through extensive and in-depth research. Unexpectedly, the crystal form APTI-I exhibits the advantages of high stability, low hygroscopicity, high purity, high solubility, etc., and the production method is simple, the quality is stable, and it is suitable for large-scale industrial production.

[0052] Resmetirol crystal form APTI-I .

[0053] The resmetirole crystal form APTI-I provided by the present invention uses Cu-Kα radiation, and its X-ray powder diffraction (XRPD) spectrum represented by 2θ angles has characteristic peaks at 5.0°±0.2°, 6.3°±0.2°, 7.8°±0.2°, 12.2°±0.2°, and 20.0°±0.2°.

[0054] Furthermore, the resmetirole crystal form APTI-I provided by the present invention uses Cu-Kα radiation, and its XRPD spectrum expressed in 2θ angles has characteristic peaks at 5.0±0.2°, 6.3±0.2°, 7.8±0.2°, 8.5±0.2°, 10.1±0.2°, 12.2±0.2°, 14.4±0.2°, 15.1±0.2°, 16.5±0.2°, 16.9±0.2°, 17.9±0.2°, 20.0±0.2°, 20.4±0.2°, 20.9±0.2°, 22.0±0.2°, 23.0±0.2°, 23.8±0.2°, 25.3±0.2°, and 26.4±0.2°.

[0055] Furthermore, the resmetirole crystal form APTI-I provided by the present invention uses Cu-Kα radiation, and its XRPD spectrum expressed in 2θ angles has characteristic peaks as shown in Table 1 below:

[0056] Table 1

[0057]

[0058]

[0059] Furthermore, the resmetirol crystal form APTI-I provided by the present invention uses Cu-Kα radiation, and its XRPD pattern expressed in 2θ angles is Figure 1 Be consistent.

[0060] Furthermore, the differential scanning calorimetry (DSC) diagram of the resmetirome crystal form APTI-I provided by the present invention has an exothermic peak at 237±5°C (peak) and an endothermic peak at 330±5°C (peak);

[0061] Furthermore, the DSC diagram of the resmetirol crystal form APTI-I provided by the present invention is Figure 2 Be consistent.

[0062] Furthermore, the thermogravimetric analysis (TGA) graph of the resmetirome crystal form APTI-I provided by the present invention shows a weight loss of about 2.7% at 40-160°C.

[0063] Furthermore, the TGA diagram of the resmetirol crystal form APTI-I provided by the present invention is Figure 3 Be consistent.

[0064] Furthermore, the polarized light microscopy (PLM) results of the resmetirome crystal form APTI-I provided by the present invention showed that the crystal morphology was rod-shaped and uniformly distributed.

[0065] Furthermore, the PLM of the resmetirome crystal form APTI-I provided by the present invention is consistent with Figure 4.

[0066] Preparation of Resmetirol Crystal Form APTI-I

[0067] The preparation method of the resmetirome crystal form APTI-I of the present invention comprises the following steps:

[0068] (1) mixing resmetiro with a first organic solvent, adding a base to the mixture to form a salt of resmetiro and dissolve it, filtering, and concentrating the filtrate to dryness to obtain an amorphous form of resmetiro salt;

[0069] (2) mixing the amorphous form of the resumetirol salt with a second organic solvent, adding an acid to the mixture to free the resumetirol salt, filtering the mixture, and drying the filter cake to obtain the resumetirol crystal form APTI-I.

[0070] Furthermore, the first organic solvent is a hydrophilic organic solvent, the second organic solvent is an ether organic solvent, the base is an aqueous solution of an inorganic base, and the acid is an aqueous solution of an inorganic acid.

[0071] Furthermore, the hydrophilic organic solvent is selected from methanol, ethanol, n-propanol, isopropanol, acetone, 2-butanone, acetonitrile, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, N,N-dimethylacetamide or a combination thereof; the ether organic solvent is selected from methyl tert-butyl ether, isopropyl ether, cyclopentyl methyl ether or a combination thereof; the inorganic base is selected from sodium hydroxide, potassium hydroxide, ammonia water or a combination thereof; the inorganic acid is selected from hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid or a combination thereof.

[0072] Furthermore, in step (1), resmetirol is mixed with the first organic solvent and stirred at 35°C to 65°C for 0.5h to 2.0h, and then a base is added, and the filtering temperature is 0 to 40°C.

[0073] Furthermore, in step (2), the amorphous resmetiro salt is mixed with the second organic solvent and stirred at 35°C to 65°C for 0.5h to 2.0h, and then the acid is added, and the filtration temperature is 0 to 40°C.

[0074] Furthermore, in step (2), the drying temperature is 40° C. to 85° C., and the drying time is 10 h to 24 h.

[0075] The amount of the hydrophilic organic solvent is not particularly limited, and is the amount commonly used for solvent pulping in the art. In some specific embodiments of the present invention, the weight-volume ratio of resmetiro to the hydrophilic organic solvent is 1g / 3mL to 15. mL. The amount of the ether organic solvent is not particularly limited, and is the amount commonly used for solvent pulping in the art. In some specific embodiments of the present invention, the weight-volume ratio of resmetiro salt to the ether organic solvent is 1g / 4mL to 20mL.

[0076] The purpose of the inorganic base is to provide cations to form salts with resmetiro and dissolve in the solvent. Therefore, in theory, the molar ratio of resmetiro to the hydroxide provided by the inorganic base is 1:1. In some specific embodiments of the present invention, in order to allow resmetiro to fully form a salt, the molar ratio of resmetiro to the hydroxide provided by the inorganic base is 1:1.0 to 1.2.

[0077] The purpose of the inorganic acid is to provide hydrogen ions, neutralize the inorganic base, and free the resmetiro salt. Therefore, in theory, the molar ratio of the hydrogen ions provided by the inorganic acid to the hydroxide provided by the base is 1:1.

[0078] The concentration of the aqueous solution of the inorganic base is not particularly limited. In some specific embodiments of the present invention, the molar concentration of the aqueous solution of the inorganic base is 1 to 3 mol / L.

[0079] The concentration of the aqueous solution of the inorganic acid is not particularly limited. In some specific embodiments of the present invention, the molar concentration of the aqueous solution of the inorganic acid is 1 to 3 mol / L.

[0080] In the description of the present invention, "room temperature" refers to 0°C to 40°C, for example, 4°C, 10°C, 25°C, 35°C, etc.

[0081] Compared with the prior art, the beneficial effects of the resmetirome crystal form APTI-I of the present invention are:

[0082] (1) The preparation method of the resmetirome crystal form APTI-I of the present invention is simpler than that of the crystal form Form I disclosed in the original research (WO2014043706A1), and the product quality obtained in production is more stable, and the product purity is good and the yield is high.

[0083] (2) The resmetirome crystal form APTI-I of the present invention exhibits good high temperature stability, grinding stability and packaging stability, and is suitable for long-term storage.

[0084] (3) Compared with the crystal form Form I disclosed in the original study (WO2014043706), the resmetirol crystal form APTI-I of the present invention exhibits higher solubility in aqueous solvents at multiple pH values, and is more conducive to the drug's efficacy as an API.

[0085] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are only intended to illustrate the present invention and are not intended to limit the scope of the present invention. The experimental methods in the following examples without specifying specific conditions are usually based on normal conditions. Unless otherwise indicated, percentages and parts are weight percentages and parts by weight.

[0086] Materials and general method:

[0087] 1. XRPD spectrum determination method

[0088] X-ray powder diffraction instrument: BRUKER AXSD2 PHASER X-ray powder diffractometer; Radiation source: Intensity ratio α1 / α2 is 0.5; Generator kv: 30.0 kv; Generator mA: 10.0 mA; Scanning range: 3.0~40.0°.

[0089] 2.DSC measurement method

[0090] METTLEER DSC1 differential scanning calorimeter temperature program: 30℃~360℃, 20℃ per minute.

[0091] 3. TGA determination method

[0092] Instrument model: METTLEER TGA / DSC1 thermogravimetric analyzer. Heating program: 30℃~400℃, 10℃ per minute.

[0093] The crude resmetirol used in the following comparative examples and examples is commercially available, and its HPLC purity is about 97.6%.

[0094] Comparative Example 1: Preparation of Crystal Form I according to the Prior Art WO2014043706

[0095] Weigh 5 g of crude resmetiro, add 25 mL of MIBK at room temperature, heat from 20-25 ° C to 50 ° C, keep warm for 1 hour, naturally cool to 20-25 ° C, keep warm for 2.5 hours, filter the product to a nearly dry state, and obtain 6.4 g of wet MIBK solvate.

[0096] The wet product of the MIBK solvate was added to 32 mL of ethanol, heated to 80 ± 5 °C in a three-necked flask, refluxed and slurried, and sampled for testing after 2 hours. XRPD testing confirmed that the product was Form I (see Figure 5 , the bottom XRPD spectrum), reflux beating for 4 hours and sampling for testing, XRPD testing confirmed that the product is Form I (see Figure 5, XRPD spectrum in the middle). The system refluxed for 4 hours was cooled naturally to 20°C (for a system of about 35 mL, it is difficult to control the temperature to 20°C in 45 minutes), and stirred for 15 minutes and filtered. The obtained product was confirmed to be an ethanol solvate by XRPD detection (see Figure 5 , the top XRPD pattern, which is consistent with WO2020010068 Figure 3 The XRPD patterns of the ethanol solvate of Compound A (resmetirole) shown are consistent.) The purity of the ethanol solvate was 98.5% as determined by HPLC.

[0097] The XRPD patterns of the product obtained by reflux beating in ethanol for 2 hours, the product obtained by reflux beating in ethanol for 4 hours, and the product obtained by filtering after the reflux system was naturally cooled to 20°C are shown in the overlay diagram. Figure 5 .from Figure 5 It can be seen that when the MIBK solvate is slurried in ethanol for 2h to 4h, the crystal form changes to generate Form I. However, when the reflux system is naturally cooled to 20°C, the crystal form obtained by filtration changes again to generate an ethanol solvate.

[0098] In the process of the scaled-up kilogram-level experiment, when the technicians refluxed and slurried the resmetiro MIBK solvate in ethanol to prepare the crystalline Form I, even if the reflux system was strictly controlled to cool to 20°C in 45 minutes, most batches obtained the crystalline Form I product, but a small number of batches still obtained the ethanol solvate of resmetiro. The batches that obtained the ethanol solvate of resmetiro were failed batches. This shows that the crystalline Form I can easily transform into the ethanol solvate in the ethanol system. This is disadvantageous in industrial scale-up production.

[0099] Comparative Example 2: Preparation of Crystal Form F according to the Prior Art WO2020010068

[0100] Weigh 200 mg of resmetiro, add 2 mL of ethyl acetate, stir magnetically at 50°C for 24 h, filter, and XRPD test confirms that the obtained product is ethyl acetate solvate (see Figure 7 , the bottom XRPD spectrum), the ethyl acetate solvate was dried under vacuum at 80°C for 12 h, and XRPD detection revealed that the solvate did not crystallize (see Figure 7 , the XRPD pattern in the middle). The ethyl acetate solvate was subjected to DSC detection, and the results are shown in Figure 6 ,from Figure 6 It can be seen that the solvate is desolvated at 148±5°C. The ethyl acetate solvate is heated to 150°C and kept at this temperature for 3 minutes before desolvation to obtain Form F (see Figure 7 , top XRPD pattern).

[0101] Crystal Form F requires heating the ethyl acetate solvate to 150°C to obtain, indicating that the temperature required for the method of desolvating the solvate to obtain the new crystal form is too high to meet the requirements of industrial large-scale production. In addition, the NMR spectrum of the product obtained after heating and desolvation showed that there was still 0.04 eq of ethyl acetate remaining, which exceeded the standard.

[0102] Example 1: Preparation of Resmetiro Crystal Form APTI-I

[0103] 5 g of crude resmetiro and 25 mL of tetrahydrofuran solvent were added to the reaction bottle, and magnetic stirring was carried out at 50 ° C for 1 h to prepare a suspension. The heating was stopped and 1.1 eq 2 mol / L NaOH aqueous solution was added to the suspension. The suspension gradually became clear. After continuous stirring for 1 h, it was filtered at room temperature. The filtrate was concentrated to dryness and slurried and filtered with MTBE (to make the residue powdery for easy removal from the reaction bottle) to obtain amorphous resmetiro sodium salt, and its XRPD spectrum is shown in Fig.12 , its H NMR spectrum can be found at Fig.13 .

[0104] Weigh 5g of the above-mentioned amorphous sodium salt of resmetirol and add it to 50mL of methyl tert-butyl ether. After stirring at 50°C for 30min, stop heating and slowly add 1.1eq of concentrated hydrochloric acid. After stirring for 1h, filter at room temperature, rinse the filter cake with 10mL of water, and vacuum dry at 50°C for 16h to obtain 4.5g of off-white solid with a purity of 99.8% and a yield of about 94.5%. XRPD detected that the white solid was crystalline APTI-I. Its XRPD spectrum can be found at Figure 1 , its DSC diagram is shown in Figure 2 , its TGA diagram can be found in Figure 3 , its PLM diagram can be found in Figure 4a , its H NMR spectrum can be found at Figure 4b Based on these spectra, it is inferred that the crystal form APTI-I is anhydrous crystalline form.

[0105] Example 2: Preparation of Resmetiro Crystal Form APTI-I

[0106] Add 5 g of crude resmetiro and 25 mL of tetrahydrofuran solvent to the reaction bottle, stir magnetically at 50 ° C for 1 hour to make a suspension, stop heating and add 1.1 eq of concentrated ammonia solution to the suspension, the suspension gradually becomes clear, continue stirring for 1 hour, filter at room temperature, and concentrate the filtrate to dryness to obtain amorphous resmetiro ammonium salt.

[0107] Weigh 5g of the above-mentioned amorphous resmetirol ammonium salt and add it to 50mL of methyl tert-butyl ether. After stirring at 50°C for 30min, stop heating and slowly add 1.1eq of concentrated hydrochloric acid to it, stir for 1h, filter at room temperature, rinse the filter cake with 10mL of water, and vacuum dry at 50°C for 16h to obtain 4.5g of off-white solid with a purity of 99.86% and a yield of about 93.7%. XRPD detection of the off-white solid showed the same Figure 1 The XRPD pattern is consistent with that of .

[0108] Example 3: Preparation of Resmetiro Crystal Form APTI-I

[0109] Add 5 g of crude resmetiro and 25 mL of tetrahydrofuran solvent to the reaction bottle, stir magnetically at 50 ° C for 1 hour to make a suspension, stop heating and add 1.1 eq 2 moL / L KOH aqueous solution to the suspension, the suspension gradually becomes clear, continue stirring for 1 hour, filter at room temperature, and concentrate the filtrate to dryness to obtain resmetiro potassium salt amorphous.

[0110] 5 g of the above-mentioned amorphous potassium salt of resmetiro was weighed and added to 50 mL of isopropyl ether. After stirring at 50 ° C for 30 min, the heating was stopped and 0.55 eq 2 mol / L sulfuric acid was slowly added thereto. After continuous stirring for 1 h, the mixture was filtered at room temperature. The filter cake was rinsed with 10 mL of water and dried in vacuo at 50 ° C for 16 h to obtain 4.2 g of an off-white solid with a purity of 99.84% and a yield of about 91.5%. The off-white solid was detected by XRPD, and the results were consistent with Figure 1 The XRPD pattern is consistent with that of .

[0111] Example 4: Grinding stability of resmetirol crystal form APTI-I

[0112] Weigh 200 mg of resmetirol crystal form APTI-I (HPLC purity 99.86%) and grind it manually in an agate grinder for 30 minutes. The ground product was detected by XRPR. The results are shown in Figure 8 (Shown is an overlay of the XRPD patterns of the starting material (Form APTI-I) and the product obtained after manual dry grinding in an agate grinder for 30 min.) Figure 8 It can be seen that the crystal form of APTI-I did not undergo crystal transformation before and after grinding. The purity of the ground product was 99.86% as determined by HPLC, with no significant change in purity compared to the starting material.

[0113] Example 5: Evaluation of high temperature stability of resmetirol crystal form APTI-I

[0114] Take 1g of resmetiro crystal form APTI-I (HPLC purity is 99.86%), place it in an oven at 80°C for 24h, then take a sample and detect its crystal form by XRPD. The results are shown in Fig. 9(It shows an overlay of the XRPD patterns of the starting material (Form APTI-I) and the product obtained after being placed in an oven at 80°C for 24 hours). Fig. 9 It can be seen that the crystal form of APTI-I did not change after being heated at 80° C. for 24 h. The purity of the product after being heated at 80° C. for 24 h was 99.84% as determined by HPLC, which was not significantly different from the starting material.

[0115] Example 6: Evaluation of the hygroscopicity of resmetirol crystal form APTI-I

[0116] Accurately weigh 1172.5 mg of solid resmetirol crystal form APTI-I (HPLC purity 99.86%) and spread it evenly in a 100 mm glass dish. After the product was left in a constant temperature and humidity chamber at 25°C / 80%RH for 24 hours, the peeled weight was 1176.8 mg, with a weight gain of 4.3 mg and a weight gain of 0.37%. According to the guidelines for the hygroscopicity test of pharmacopoeia drugs, the weight gain due to moisture is less than 2% but not less than 0.2%, indicating that crystal form APTI-I is slightly hygroscopic. XRPD was used to detect the product after being left in a constant temperature and humidity chamber at 25°C / 80%RH for 24 hours. The results are shown in Table 1. Fig.10 (which shows an overlay of the XRPD patterns of the starting material (crystalline APTI-I) and the product obtained after being exposed in a constant temperature and humidity chamber at 25°C / 80%RH for 24 hours). Fig.10 It can be seen that the crystal form of APTI-I did not change after being placed at 25°C / 80%RH for 24 hours. The purity of the product after being placed at 25°C / 80%RH for 24 hours was 99.87% by HPLC, which was not significantly different from the starting material.

[0117] Example 7: Temperature and humidity stability of resmetirol crystal form APTI-I

[0118] Resmetirol crystal form APTI-I was packaged in PE bags and aluminum foil bags (i.e., the product had two layers of packaging, first in PE bags and then in aluminum foil bags), and then placed at 25°C / 60%RH and 40°C / 70%RH, respectively. Samples were taken for XRPD detection and purity detection after 1 week and 2 weeks, respectively. The XRPD pattern of the obtained product was shown in the overlay diagram. Fig.11 (It shows the XRPD patterns of the starting material (crystalline APTI-I), the product packaged in PE bags and aluminum foil bags and placed at 25°C / 60%RH for 1 week, the product packaged in PE bags and aluminum foil bags and placed at 40°C / 75%RH for 1 week, the product packaged in PE bags and aluminum foil bags and placed at 25°C / 60%RH for 2 weeks, and the product packaged in PE bags and aluminum foil bags and placed at 40°C / 75%RH for 2 weeks. The XRPD patterns of these products are arranged from bottom to top.) The purity of the products is shown in Table 2 below. Fig.11As can be seen from Table 2, after the resmetiro crystal form APTI-I was packaged in PE bags and aluminum foil bags and placed at 25°C / 60% RH and 40°C / 70% RH for 1 week or 2 weeks, there was no obvious change in the crystal form and purity, indicating that the resmetiro crystal form APTI-I was stable under 25°C / 60% RH and 40°C / 70% RH conditions after being packaged in PE bags and aluminum foil bags, and was suitable for storage.

[0119] The evaluation conditions of Examples 5-7 and the crystal forms and purities of the products obtained after the experiments are summarized in Table 2 below.

[0120] Table 2

[0121]

[0122] Example 8: Solubility evaluation of resmetirol crystalline form APTI-I and crystalline form I in aqueous media at different pH values

[0123] The method for preparing aqueous media with different pH values ​​(all aqueous media with different pH values ​​have a uniform ion concentration of 50 mM) is as follows:

[0124] Preparation of pH 1.2 buffer: add 167 μL (2 mmoL) of 36.5% hydrochloric acid to 80 mL of water, then add 0.223 g KCl (3 mmoL), dissolve by ultrasonication, adjust the pH of the system to 1.2 ± 0.1 with hydrochloric acid (mass concentration of 10%) or / and NaOH aqueous solution (mass concentration of 15%), and then calibrate to 100 mL;

[0125] Preparation of pH 4.5 buffer: add 2.75mmoL of acetic acid to 80mL of water, then add 2.25mmoL of sodium acetate, adjust the pH of the system to 4.5±0.2 with hydrochloric acid or sodium hydroxide aqueous solution, and then titrate to 100mL;

[0126] Preparation of pH 6.8 buffer: add 2.45 mmol of disodium hydrogen phosphate and 2.55 mmol of sodium dihydrogen phosphate to 80 mL of water, adjust the pH of the system to 6.8 ± 0.2 with hydrochloric acid (mass concentration of 10%) or / and sodium hydroxide aqueous solution (mass concentration of 15%), and then titrate to 100 mL;

[0127] Water: deionized water.

[0128] 2. Solubility test

[0129] Weigh four portions of 100 mg of crystalline Form I and four portions of crystalline APTI-I, add 10 mL of pH 1.2 buffer, pH 4.5 buffer, pH 6.8 buffer and water, respectively, stir magnetically at 37°C, take samples and filter and dilute 2 times at 1 hour and 24 hours, and perform HPLC detection on the filtrate. The concentration results are summarized in Table 3 below. As can be seen from Table 3, the 1h solubility data results show that the solubility of crystalline APTI-I in all aqueous solvents is 1.2 to 1.6 times that of crystalline Form I, and the 24h solubility results show that the solubility of crystalline APTI-I and crystalline Form I in pH 1.2 buffer and pH 4.5 buffer is reduced, and the solubility is similar. In water, the 24h solubility results show that the solubility of crystalline APTI-I is 1.9 times that of crystalline Form I, and the solubility of crystalline APTI-I in pH 6.8 buffer is also significantly higher than that of crystalline Form I. Therefore, in terms of solubility in aqueous solvents with different pH values, crystalline APTI-I shows obvious advantages over crystalline Form I.

[0130] Table 3

[0131]

[0132] In summary, the resmetirome crystal form APTI-I obtained by the present invention is a new crystal form different from the crystal form disclosed in the prior art. Compared with the original crystal form Form I, this crystal form has a simpler preparation method, the target product has high purity and high yield, and can be prepared more stably in production. At the same time, the crystal form APTI-I exhibits good high temperature resistance, grinding stability, and packaging stability, making the crystal form APTI-I more suitable for storage. In the solubility evaluation in aqueous solvents of different pH values, the crystal form APTI-I unexpectedly exhibits higher solubility than the original crystal form Form I, which is more conducive to the drug exerting its efficacy. It can be seen that the crystal form APTI-I provided by the present invention exhibits obvious advantages in production, preparation, storage, transportation and use.

[0133] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

Claims

1. A resmetirome crystal form APTI-I, characterized in that: Using Cu-Kα radiation, its X-ray powder diffraction pattern expressed in 2θ angles has characteristic peaks at 5.0°±0.2°, 6.3°±0.2°, 7.8°±0.2°, 12.2°±0.2°, and 20.0°±0.2°.

2. The resmetirome crystal form APTI-I according to claim 1, characterized in that: Using Cu-Kα radiation, its X-ray powder diffraction pattern expressed in 2θ angles also has characteristic peaks at any one or more of 8.5°±0.2°, 10.1°±0.2°, 14.4°±0.2°, 15.1°±0.2°, 16.5°±0.2°, 16.9°±0.2°, 17.9°±0.2°, 20.4°±0.2°, 20.9°±0.2°, 22.0°±0.2°, 23.0°±0.2°, 23.8°±0.2°, 25.3°±0.2°, and 26.4°±0.2°.

3. The resmetirome crystal form APTI-I according to claim 1, characterized in that: The resmetirol crystal form APTI-I also has one or more of the following characteristics: (i) Its X-ray powder diffraction pattern is basically as shown in Figure 1, (ii) Its differential scanning calorimetry analysis chart has an exothermic peak at 237±5℃ and an endothermic peak at 330±5℃. (iii) Its differential scanning calorimetry analysis diagram is basically as shown in FIG2 , (iv) Its thermogravimetric analysis shows a weight loss of about 2.7% at 40-160°C. (v) Its thermogravimetric analysis diagram is basically as shown in Figure 3.

4. The method for preparing the resmetirome crystal form APTI-I according to any one of claims 1 to 3, characterized in that: The preparation method comprises the following steps: (1) mixing resmetiro with a first organic solvent, adding a base to the mixture to form a salt of resmetiro and dissolve it, filtering, and concentrating the filtrate to dryness to obtain an amorphous form of resmetiro salt; (2) mixing the amorphous form of the resumetirol salt with a second organic solvent, adding an acid to the mixture to free the resumetirol salt, filtering the mixture, and drying the filter cake to obtain the resumetirol crystal form APTI-I.

5. The preparation method according to claim 4, characterized in that: The first organic solvent is a hydrophilic organic solvent, and / or The second organic solvent is an ether organic solvent, and / or The base is an aqueous solution of an inorganic base, and / or The acid is an aqueous solution of an inorganic acid.

6. The preparation method according to claim 5, characterized in that: The hydrophilic organic solvent is selected from methanol, ethanol, n-propanol, isopropanol, acetone, 2-butanone, acetonitrile, tetrahydrofuran, 1,4-dioxane, N,N-dimethylformamide, N,N-dimethylacetamide or a combination thereof, more preferably, tetrahydrofuran, and / or The ether organic solvent is selected from methyl tert-butyl ether, isopropyl ether, cyclopentyl methyl ether, etc., preferably methyl tert-butyl ether or a combination thereof, more preferably methyl tert-butyl ether, and / or The inorganic base is selected from sodium hydroxide, potassium hydroxide, ammonia or a combination thereof, more preferably, sodium hydroxide, and / or The inorganic acid is selected from hydrochloric acid, sulfuric acid, nitric acid, hydrobromic acid or a combination thereof, more preferably, hydrochloric acid.

7. The preparation method according to claim 5, characterized in that: The weight-to-volume ratio of resmetiro to the hydrophilic organic solvent is 1 g / 3 mL to 15 mL, more preferably, 1 g / 4 mL to 6 mL, and / or The weight-to-volume ratio of resmetiro salt to ether organic solvent is 1 g / 4 mL to 20 mL, more preferably, 1 g / 8 mL to 12 mL, and / or The molar ratio of resmetirol to the hydroxide provided by the inorganic base is 1:1.0-2.0, more preferably 1:1.0-1.2, most preferably 1:1.1, and / or The molar ratio of hydrogen ions provided by the inorganic acid to hydroxide ions provided by the base is 1:0.8-1.2, preferably 1:1, and / or The molar concentration of the aqueous solution of the inorganic base is 1 to 3 mol / L, and / or The molar concentration of the aqueous solution of the inorganic acid is 1 to 3 mol / L.

8. The preparation method according to claim 4, characterized in that: In step (2), the drying temperature is 40°C to 85°C, and the drying time is 10h to 24h. More preferably, the drying temperature is 50°C to 70°C, and the drying time is 12h to 20h.

9. The preparation method according to claim 4, characterized in that: In step (1), resmetirol is mixed with the first organic solvent and stirred at 35°C to 65°C for 0.5h to 2.0h, then a base is added, and the filtration temperature is 0 to 40°C; and / or In step (2), the amorphous resmetiro salt is mixed with the second organic solvent and stirred at 35°C to 65°C for 0.5h to 2.0h, and then an acid is added, and the filtration temperature is 0 to 40°C.

10. A pharmaceutical composition comprising the resmetirome crystal form APTI-I according to any one of claims 1 to 3.

Citation Information

Cited By

  • Rosmeltirol crystal form and preparation method thereof

    CN119954780A

  • New crystal form of rosemeltirol and preparation method thereof

    CN120247881A

  • A new crystalline form of resminostat and a process for its preparation

    CN120247881B

  • Rosemeltirome-aminopyridine monohydrate crystal form and preparation method thereof

    CN122010909A

  • New crystal form of resmetirom and preparation method therefor

    WO2026036854A1